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Abstract In view of the essential role of the hemopexin domain
of the traditional interstitial collagenases, MMP-1, -8, -13 and
MT1-MMP (MMP-14), in determining specific collagen clea-
vage we have studied the function of this domain in MMP-2,
relative to that of the fibronectin-like domain that promotes
gelatinolysis. Although the fibronectin-like domain promotes
avid binding to collagen, our data demonstrate that the catalytic
and hemopexin domains of MMP-2 are sufficient to effect the
critical step in cleavage of rat type I collagen into 3/4 and 1/4
fragments. The mechanism of MMP-2 cleavage of collagen
proceeds in two phases, the first resembling that of the interstitial
collagenases, followed by gelatinolysis, promoted by the
fibronectin-like domain. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
It has been shown previously that gelatinase A, MMP-2,
could cleave both soluble and reconstituted ¢brillar collagen
[1], although this observation has been disputed [2]. Like all
the collagenolytic MMPs, MMP-2 cleaves at a single site with-
in the K1 and K2 chains of type I collagen (Gly775-Ileu776/
Leu), which generate the classical 3/4 and 1/4 cleavage frag-
ments [3]. However, it is notable that, whereas the speci¢c
collagenases have Km values in the 1^2 WM range for type I
collagens [4,5], the value for MMP-2 is around 8.5 WM [1].
Previous studies on the interaction of the collagenolytic
MMPs with ¢brillar collagen have established the importance
of the hemopexin domain in both binding to and cleavage of
this substrate [6^10]. However, MMP-3 (stromelysin 1) has a
hemopexin domain that binds collagen but this does not sup-
port collagenolysis by MMP-3, or by a chimera constructed
from the catalytic domain of MMP-1 and the hemopexin
domain of MMP-3 [7,8]. The need for the speci¢c interactions
between catalytic and hemopexin domains of the collagenases
has been discussed by Bode [11] and Murphy and Kna«uper
[12].
MMP-2 also binds tightly to native or denatured collagens
and it has been shown that this is predominantly mediated by
the three ¢bronectin type II-like repeats, the gelatin binding
region, which are localised within the catalytic domain [13].
Deletion of this ¢bronectin-like domain apparently abolishes
collagen binding and signi¢cantly abrogates the gelatinolytic
capacity of MMP-2, without a¡ecting the ability to cleave
peptide substrates or to bind TIMP-1 or TIMP-2 [14]. Fur-
thermore, the isolated recombinant forms of the ¢bronectin
type II-like modules of MMP-2 were shown to bind gelatin
[15]. Work by Ste¡ensen et al. [16] identi¢ed at least two
binding sites in the recombinant ¢bronectin-like domain for
gelatin and native type I collagen. More recently synthetic
triple helical peptides describing the cleavage site of type I
collagen have been synthesised [17] and shown to bind wild-
type MMP-1 and MMP-8 as well as MMP-2. However, the
deletion mutant of MMP-2 lacking the ¢bronectin-like do-
main failed to bind to these synthetic triple helical peptides
which indicates that this structural element of MMP-2 is es-
sential for e⁄cient binding [18]. The hemopexin domain of
MMP-2 showed no apparent contribution to binding to type
I collagen [19,20].
In view of these data it was interesting to speculate how the
mode of interaction with MMP-2 to native collagens relates to
its modest collagenolytic capacity. In this study we compare
the relative collagenolytic activities of full length MMP-2, and
two deletion mutants lacking either the ¢bronectin-like or the
hemopexin domains. Our results indicate a novel biphasic
collagenolytic mechanism of action of MMP-2, where the ini-
tial cleavage resembles that of the other speci¢c collagenases,
followed by further degradation of the 1/4 and 3/4 fragments.
2. Materials and methods
2.1. Preparation and activation of enzymes and active site titration
The following were expressed and puri¢ed from myeloma cell con-
ditioned medium: human proMMP-2 [8], prov191ÿ364 MMP-2 (vGBR
MMP-2) [14], prov418ÿ631 MMP-2 (N-terminal MMP-2) [8] and hu-
man MMP-1 [21]. Recombinant human MMP-3 was expressed and
puri¢ed as described [22]. A transmembrane and cytoplasmic tail de-
letion mutant of human MT1-MMP was expressed in Escherichia coli
and refolded as described previously [23].
MMP-1 was ‘superactivated’ by incubation with 10 Wg/ml trypsin
(Sigma, cat. No. T-8253) in the presence of active MMP-3 (at a 10:1
molar ratio) for 15 min at 37‡C. MMP-3 was activated by incubation
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with 10 Wg/ml trypsin for 15 min at 37‡C. In both cases activation was
stopped with of 100 Wg/ml soya bean trypsin inhibitor.
MMP-2 and the two domain deletion mutants were activated by
incubation with 2 mM APMA for 1 h at 25‡C, followed by SDS^
PAGE analysis [24] to ensure that minimal loss of the C-terminal
domain had occurred.
All enzymes were active site titrated with varying known amounts
of TIMP-1 (MMP-1 and MMP-3) or TIMP-2 (MMP-2 and the do-
main deletion mutants) [25] using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-NH2 as a substrate for MMP-2 and the two domain deletion
mutants. Mca-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 was employed
for active site titrations of MMP-1 and MMP-3. The enzyme^TIMP
complexes were added to 1 WM quenched £uorescent substrate in
bu¡er (50 mM Tris^HCl pH 7.5, 200 mM NaCl, 5 mM CaCl2,
0.05% Brij 35) and linear substrate hydrolysis was monitored using
a Perkin Elmer LS50B £uorimeter.
2.2. Preparation of collagens and collagenolysis assays
Acid soluble rat skin type I collagen (both unlabelled and 14C
acetylated) was prepared as described previously [26]. Acid soluble
bovine skin type I collagen (both unlabelled and 3H labelled) was a
generous gift from T. Cawston. In all experiments using type I colla-
gen the substrate was incubated for 2 h at 35‡C to allow formation of
¢brils, thus the substrate is in the solid phase. In attempts to carry out
incubations using soluble collagen it was not possible to prevent ¢bril
formation, hence preformed ¢brils gave some uniformity of substrate.
Collagenolysis of radiolabelled collagen was assayed as follows: active
enzymes of known concentrations were added to 100 Wg radiolabelled
triple helical type I collagen ¢brils, 50 Wl 2UTris assay bu¡er (200
mM Tris^HCl pH 8.0, 60 mM CaCl2) added, and made up to 300 Wl
with water. The samples were incubated at 35‡C for 4 h and then
centrifuged for 15 min at 12 000 rpm at 4‡C to pellet the uncleaved
collagen and radioactivity was counted from the supernatant. Colla-
gen released (Wg) was plotted against enzyme concentration, and units/
nmol were calculated from the linear portions of the graphs. 15% of
the rat skin type I collagen was bu¡er soluble and a further 2% was
trypsin sensitive, while 30% of the bovine skin type I collagen was
bu¡er soluble and a further 9% was trypsin sensitive. 60 Wg unlabelled
type I collagen was cleaved for 2 h at 25‡C with active site titrated
enzymes in a total volume of 200 Wl in salt free bu¡er (50 mM Tris^
HCl pH 7.6, 5 mM CaCl2). For type II collagen 20 Wg of substrate
was cleaved in a total volume of 60 Wl salt free bu¡er for 2 h at 25‡C.
The reactions were stopped with 50 mM EDTA (¢nal concentration)
and su⁄cient four times reducing sample bu¡er prior to boiling for 10
min. Samples were applied to 7.5% SDS^PAGE and all gels were
stained with Coomassie brilliant blue G. Densitometry (using Gel-
Works 1D) was used to analyse the SDS^PAGE gels of cleavage of
type II collagen. Samples were loaded in triplicate and the average
rate of cleavage (Wg collagen/min) was calculated for each enzyme and
converted to speci¢c activity (units/nmol).
2.3. Degradation of 14C type 1 collagen ¢lms by puri¢ed recombinant
MMPs
14C type I collagen ¢lms were prepared according to the method of
Atkinson et al. [27]. Active forms of puri¢ed recombinant MMP-1,
MMP-2, vGBR MMP-2 and MT1-MMP, prepared as described
above, or bu¡er alone were incubated on washed ¢lms at the concen-
trations indicated in 100 mM Tris^HCl pH 7.6, 30 mM CaCl2, 0.05%
Brij 35 for 18 h at 37‡C. Supernatants were harvested, centrifuged at
10 000 rpm for 10 min to remove undigested collagen and aliquots
were counted as described above. Collagen remaining in the wells was
digested with 50 Wg/ml bacterial collagenase and counted as before so
that total counts could be estimated.
3. Results and discussion
A number of laboratories have studied the ability of MMP-
2 to cleave native collagens, which has generated substantial
debate and controversy [1,2,28]. The aim of this study was to
investigate whether MMP-2 is a true collagenolytic MMP
and, if so, how its mechanism of action is determined by
the di¡erent domains of the enzyme and how this relates to
the mechanism of the conventional interstitial collagenases,
MMP-1, MMP-8, MMP-13 and MT1-MMP, which is depen-
dent on the C-terminal hemopexin domain. Since collagenol-
ysis of triple helical collagens is highly dependent on the qual-
ity of the substrate preparation and the amount of ¢brils
present, we used two highly trypsin resistant type I collagen
preparations (of rat or bovine origin) for our comparative
analysis of collagenolysis of wild-type MMP-2 and two dele-
tion mutants lacking either the ¢bronectin-like (vGBR MMP-
2) or the hemopexin domains of MMP-2 (N-terminal MMP-
2), relative to the collagenolytic activity of ‘superactivated’
MMP-1. To ensure speci¢city, all assays were performed
with preformed collagen ¢brils and linearity of collagenolytic
assays was established for all enzyme preparations over time.
3.1. Domain requirements of MMP-2 in collagenolysis: the
role of the ¢bronectin-like and hemopexin domains of
MMP-2 in determining speci¢c type I collagen cleavage
In order to con¢rm that MMP-2 cleaved native collagen in
the ‘1/4, 3/4 clip’ fashion considered unique to the speci¢c
collagenases, we carried out incubations of preformed ¢brils
at 25‡C followed by SDS^PAGE analysis of the respective
MMP cleavage products (Fig. 1). Our results revealed that
MMP-1 generated only 1/4 and 3/4 fragments (Fig. 1, lane
5), whilst MMP-2 produced comparable fragments but pro-
ceeded to degrade them further (Fig. 1, lane 2). While the N-
terminal MMP-2 was unable to cleave collagen ¢brils (Fig. 1,
lane 3, Fig. 2), the mutant lacking the ¢bronectin type II
repeats (vGBR MMP-2) displayed considerable collagenolytic
activity with the generation of the classical 1/4 and 3/4 cleav-
age products of the interstitial collagenases (Fig. 1, lane 4,
Fig. 2, Table 1). The vGBR mutant was also active against
dried collagen ¢lms (Fig. 4), thus demonstrating that this
activity is strongly dependent on the C-terminal hemopexin
domain, a feature shared with the other collagenases (MMP-1,
MMP-8, MMP-13 and MT1-MMP) [12,26]. Furthermore, the
mutant lacking the ¢bronectin type II repeats (vGBR MMP-
2) showed impaired ability to cleave the 3/4 fragments further,
indicating that this activity of the wild-type enzyme is depen-
dent on the ¢bronectin type II repeats (Fig. 1, lane 2). In the
presence of the ¢bronectin-like domain, which binds tightly to
Fig. 1. Polyacrylamide gel electrophoretic analysis of rat skin type I
collagen cleavage by MMP-1, MMP-3, MMP-2 and MMP-2 domain
deletion mutants. Cleavage of native, acid soluble ¢brillar rat skin
type I collagen. The collagen was incubated for 2 h at 35‡C to al-
low ¢brils to form. 100 nM enzyme was added to 1 WM collagen
and incubated at 25‡C for 2 h. Lanes: 1, collagen incubated with
bu¡er alone; 2, collagen incubated with MMP-2; 3, collagen incu-
bated with N-terminal MMP-2; 4, collagen incubated with vGBR
MMP-2; 5, collagen incubated with ‘superactivated’ MMP-1; 6, col-
lagen incubated with MMP-3; 7, collagen incubated with 110 nM
trypsin. The arrows on the left indicate further degradation products
of the collagen cleaved by MMP-2.
FEBS 25131 13-8-01
M.L. Patterson et al./FEBS Letters 503 (2001) 158^162 159
both collagen and gelatin [15,16,19], further breakdown of the
1/4 and 3/4 fragments occurs, even at 25‡C, which is generally
regarded as insu⁄cient to denature the 3/4 fragment. This
suggests that the ¢bronectin-like domain partially unfolds
the speci¢c 1/4 and 3/4 fragments allowing gelatinolysis to
occur by MMP-2.
Our data thus con¢rm that MMP-2 can e¡ect speci¢c col-
lagenolysis and compare favourably with the results of Aimes
and Quigley [1] and Konttinen et al. [29]. Seltzer and Eisen [2]
have suggested that MMP-2 is able to cleave any collagenous
sequence in which the helicity is not perfect. It is clear that
our preparations of collagen are highly trypsin resistant, but
we have found that di¡erent forms (partially soluble or ¢bril-
lar) have di¡ering susceptibilities to all proteinases, even the
‘true’ interstitial collagenases which are markedly more active
on soluble collagen (data not shown). Our study has shown
that speci¢c 1/4 and 3/4 cleavage of collagen by MMP-2 does
occur and it involves co-operation between the catalytic and
hemopexin domains, comparable to the other collagenases,
rather than between the catalytic and ¢bronectin-like do-
mains, as occurs for gelatin or cleavage of the 3/4 collagen
fragment (further discussed below). Thus the hemopexin do-
main of all collagenolytic MMPs discovered to date plays a
unique role in triple helical substrate recognition and cleavage
to the 1/4 and 3/4 fragments. Speci¢c collagenolysis is also
dependent on the catalytic domain [30,31] as well as the hinge
region [32]. C-Terminal domain exchanges between collageno-
lytic MMPs do not result in the generation of e⁄cient colla-
genolytic chimeric enzymes (data not shown), suggesting that
these domains cooperate in cleavage of the triple helical sub-
strates using sequence motifs which are not interchangeable
between di¡erent MMPs of the collagenase subfamily.
3.2. Quantitative analysis of rat type I, bovine type I and
bovine type II collagen degradation and comparison of the
speci¢c collagenolytic activity of wild-type and mutant
MMP-2 and MMP-1
For a quantitative analysis, 14C labelled rat type I collagen
¢brils were incubated with either MMP-2 or MMP-1 at 35‡C
and the speci¢c collagenolytic activities were determined.
MMP-2 had about 60% of the speci¢c activity of MMP-1
(Fig. 2, Table 1). The comparison of the speci¢c collagenolytic
activities of vGBR MMP-2 and wild-type MMP-2 revealed
that this mutant displayed only 38% of the activity of wild-
type MMP-2 (Fig. 2, Table 1), implying that the ¢bronectin
type II repeats potentiate activity of the wild-type enzyme in
this assay. For comparison, MT1-MMP had a speci¢c activity
that was 10% of that for superactivated MMP-1 (Table 1). At
comparable enzyme concentrations neither MMP-3 nor
MMP-9 had any activity against rat type I collagen ¢brils,
thus demonstrating that our type I collagen preparation was
resistant to non-speci¢c cleavage, i.e. contained negligible
amounts of denatured collagen, and that the other member
of the gelatinase subgroup, MMP-9, does not belong to the
collagenolytic MMPs.
In order to establish whether the observations made with
collagen type I derived from rat skin were due to possible
peculiarities of material from this species, we repeated our
comparison of MMP-2 and MMP-1 using bovine skin derived
acid soluble type I collagen. Fig. 3 shows that MMP-1 cleaved
this collagen into the 3/4 fragment whilst MMP-2 rapidly
degraded the 3/4 fragment into smaller fragments con¢rming
our results obtained with rat type I collagen. In a quantitative
¢brillar assay MMP-2 had 87% of the activity of MMP-1
Fig. 2. Cleavage of rat skin type I collagen ¢brils by MMP-1,
MMP-3, MMP-2 and MMP-2 domain deletion mutants. Cleavage
of preformed ¢brils of native, acid soluble rat skin type I collagen
as measured using 14C labelled collagen. 100 Wg 14C acetylated rat
skin type I collagen was incubated for 2 h at 35‡C to allow ¢brils
to form. Enzymes were then added and the mixture made up to 300
Wl, and incubated for 4 h at 35‡C. The graph shows Wg collagen re-
leased plotted against nM enzyme. 8, MMP-2; F, vGBR MMP-2;
R, N-terminal MMP-2; U, ‘superactivated’ MMP-1; a, MMP-3.
The solid line shows the amount of collagen that is bu¡er soluble
and the dotted line shows the amount of collagen that is additional-
ly susceptible to trypsin cleavage.
Table 1
Speci¢c activities of MMP-1, MMP-2 and mutants of MMP-2
against rat and bovine skin, acid soluble, type I collagen and bovine
articular cartilage, acid soluble, type II collagen (units/nmol)
Rat type I
collagen
Bovine type I
collagen
Bovine type II
collagen
MMP-1 30 15 20
MMP-2 18 13 5
vGBR MMP-2 7 ^ 4
N-Terminal MMP-2 0 ^ ^
MMP-3 0 0 ^
MT1-MMP 3 ^ ^
The assays were carried out as described in Section 2; type I colla-
gen was incubated at 35‡C for 4 h, type II collagen was incubated
at 25‡C for 2 h. Data are from representative experiments.
Fig. 3. Polyacrylamide gel electrophoretic analysis of bovine skin
type I collagen cleavage by MMP-1, MMP-2 and MMP-3. Cleavage
of native, acid soluble ¢brillar bovine skin type I collagen. The col-
lagen was incubated for 2 h at 35‡C to allow ¢brils to form. 100
nM enzyme was added to 1 WM collagen and incubated at 25‡C for
2 h. Lanes: 1, collagen incubated with bu¡er alone; 2, collagen in-
cubated with MMP-2; 3, collagen incubated with ‘superactivated’
MMP-1; 4, collagen incubated with MMP-3; 5, collagen incubated
with 110 nM trypsin.
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(Table 1). It is worthwhile noting that the speci¢c activities
vary for the di¡erent collagens from di¡erent species, but we
were unable to produce values for kinetic constants due to the
variation in the number of substrate cleavage sites for the two
enzymes and the ¢brillar status of the collagen.
We also compared the di¡erent enzymes in their ability to
solubilise insoluble ¢lms of rat skin type I collagen at 37‡C.
MMP-1 was most e⁄cient at low enzyme concentrations and
MT1-MMP was far less active. In general, the data for MMP-
2 and vGBR MMP-2 were similar to those obtained using
collagen ¢brils (Fig. 4). It is interesting to note that MMP-2
cleaves type I collagen more e⁄ciently than MT1-MMP under
these conditions.
The ability of MMP-2 to cleave bovine type II collagen was
examined by SDS^PAGE analysis of cleavage of the soluble
collagen at 25‡C (Fig. 5). MMP-2 is capable of cleaving this
collagen into the typical 1/4 and 3/4 fragments but to a much
lesser extent than ‘superactivated’ MMP-1. Unlike MMP-1,
MMP-2 cleaves the 1/4 and 3/4 fragments further, con¢rming
the data obtained for type I collagen of rat or bovine origin.
As a consequence, only speci¢c activity values could be as-
signed to the MMPs for collagen II cleavage (Table 1).
Our quantitative analysis of type I and II collagen con-
¢rmed that the C-terminal region of MMP-2 was required
for collagenolysis to occur. Furthermore, these assays revealed
that the ¢bronectin-like domain was required for most e⁄-
cient cleavage, since vGBR MMP-2 displayed only 38% of
wild-type MMP-2 activity. This might suggest that the ¢bro-
nectin type II repeats have a role in promoting e⁄cient en-
zyme^substrate binding and cleavage or that the ¢bronectin
type II repeats may participate in unfolding the ¢brillar sub-
strate. This was further analysed by incubating collagen ¢brils
with an equimolar amount or two-fold molar excess of an
inactive proMMP-2 mutant (E375A MMP-2) in the presence
of vGBR MMP-2 (data not shown). The e¡ective presence of
an excess of the ¢bronectin-like domain increased the collage-
nolytic activity of vGBR MMP-2, although pro-E375A
MMP-2 alone has no activity. However, SDS^PAGE analysis
of the 25‡C cleavage products from this assay showed only the
speci¢c 1/4 and 3/4 cleavage products and no further degra-
dation, as seen with wild-type MMP-2. It is therefore likely
that the inactive gelatinase had a modest e¡ect on the physical
status or helicity of the collagen only allowing more rapid
cleavage by vGBR MMP-2.
Thus from our analysis of the cleavage events it may be
concluded that triple helical collagens are hydrolysed in a
novel biphasic mechanism by wild-type MMP-2. The initial
cleavage generating the 1/4 and 3/4 fragments is strongly de-
pendent on the presence of the hemopexin-like C-terminal
domain, while further hydrolysis is promoted by the ¢bronec-
tin type II repeats, resulting in rapid clearance of the initial
degradation products.
The importance of MMP-2 in the cleavage of triple helical
collagen is not clear, since MMP-2 can be localised at the cell
surface ‘receptor’ formed by MT1-MMP^TIMP2 complexes
[23], it could play a role in focal collagenolysis, as MT1-
MMP itself may also do. The collagenolytic capacity of
MT1-MMP is relatively modest against ¢brillar or insoluble
collagen. A major function of MMP-2 in this situation could
therefore still be in the potentiation of the initial cleavage and
the further degradation of denatured collagen [33].
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